CAPLIPOINT
Caplin Point Laboratories Limited
Each stock's 10,000-path forecast, rendered as light.
Caplin Point Laboratories Limited (CAPLIPOINT) Stock Analysis & Case Study
Is CAPLIPOINT a good buy? The data-driven verdict.
Caplin Point Laboratories Limited (CAPLIPOINT) trades at ₹2,574,on the numbers it worth a closer look, a Downstox Snapshot Score of 58/100.
On the numbers, Caplin Point Laboratories Limited (CAPLIPOINT) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 30.5× earnings, ROE of 20.6%, a 54% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
CAPLIPOINT fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How CAPLIPOINT ranks against the 2,373 companies in our screener
- CAPLIPOINT's market cap of 19,566 Cr ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CAPLIPOINT's book value of ₹472 ranks in the 89th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CAPLIPOINT's promoter holding of 70.6% ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CAPLIPOINT's 3-year profit (PAT) growth of 20.0% ranks in the 57th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CAPLIPOINT's 3-year revenue growth of 14.0% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a debt-to-equity ratio figure for CAPLIPOINT, as of 9 Aug 2026, so it is not ranked here.
Is CAPLIPOINT overvalued? CAPLIPOINT P/E vs peers
CAPLIPOINT trades at 30.5× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
CAPLIPOINT share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of CAPLIPOINT history (24%/yr drift, 42%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| CAPLIPOINT 2027 | ₹1,574 | ₹2,688 | ₹4,591 | +4% |
| CAPLIPOINT 2028 | ₹1,329 | ₹2,808 | ₹5,931 | +9% |
| CAPLIPOINT 2029 | ₹1,175 | ₹2,932 | ₹7,316 | +14% |
| CAPLIPOINT 2030 | ₹1,065 | ₹3,063 | ₹8,806 | +19% |
| CAPLIPOINT 2031 | ₹975 | ₹3,199 | ₹10,491 | +24% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability CAPLIPOINT goes up, or doubles?
The bull case for CAPLIPOINT
- CAPLIPOINT's return on equity of 20.6% ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CAPLIPOINT's return on capital employed of 24.6% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹7,316.
The bear case & risks
- CAPLIPOINT's P/E of 30.5x is lower than 45% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,175.
CAPLIPOINT volatility & expected range, how bumpy is the ride?
Over the last 9.8 years CAPLIPOINT compounded at 24%/year with annualized volatility of 42%. That volatility implies a 1-year 80% range of ₹1,574-₹4,591, the honest backbone behind any single price target.
CAPLIPOINT price forecast, the full 60-month probability fan
CAPLIPOINT price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds CAPLIPOINT hits common targets within the simulated horizon?
Full multi-horizon detail on the CAPLIPOINT price target & forecast page.
CAPLIPOINT Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. CAPLIPOINT scores 6/8, mixed financial health.
CAPLIPOINT MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy CAPLIPOINT with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 32.42% | 3.1× |
| Zerodha | 32.38% | 3.1× |
| Groww | 32.52% | 3.1× |
| Dhan | 32.38% | 3.1× |
| Kotak NeoCHEAPEST | 32.36% | 3.1× |
| Paytm Money | 32.59% | 3.1× |
| Pocketful | 32.37% | 3.1× |
| Anand Rathi | 32.38% | 3.1× |
| Bajaj Broking | 43.00% | 2.3× |
| Share India | 32.51% | 3.1× |
Compare every broker on the CAPLIPOINT MTF page.
About Caplin Point Laboratories Limited: sector, index & market-cap context
Caplin Point Laboratories Limited (CAPLIPOINT) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹19,566 Cr. See more stocks on our screener.
How the CAPLIPOINT Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Caplin Point Laboratories Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
CAPLIPOINT analysis, FAQs
Is Caplin Point Laboratories Limited (CAPLIPOINT) a good buy?
On the numbers, Caplin Point Laboratories Limited (CAPLIPOINT) worth a closer look, a Downstox Snapshot Score of 58/100, weighing premium at 30.5× earnings, ROE of 20.6%, a 54% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is CAPLIPOINT overvalued or undervalued?
CAPLIPOINT trades at 30.5× earnings, premium versus the ~22× long-run Nifty average.
What is the CAPLIPOINT share price target for 2031?
CAPLIPOINT's probability-weighted 2031 median target is ₹3,199, with an 80% range of ₹975-₹10,491 (10,000-path Monte-Carlo).
What is the probability CAPLIPOINT doubles in 5 years?
The modelled probability of CAPLIPOINT reaching ₹5,148 (2×) within 5 years is 31%.
What is the bull case for CAPLIPOINT?
CAPLIPOINT's return on equity of 20.6% ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. CAPLIPOINT's return on capital employed of 24.6% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in CAPLIPOINT?
CAPLIPOINT's P/E of 30.5x is lower than 45% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.